Skip to search formSkip to main contentSkip to account menu

anacetrapib

A cholesteryl ester transfer protein (CETP) inhibitor with hypocholesterolemic properties. Anacetrapib reduces the transfer of cholesteryl ester from… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Supplemental Digital Content is available in the text. 
2017
2017
Former baseball manager Tony La Russa once said, “Even when you have three strikes, you’re still not out. There is always… 
Highly Cited
2012
Highly Cited
2012
Tangier disease is one of the most severe forms of familial high-density lipoprotein (HDL) deficiency. Since its discovery it has… 
2011
2011
A (MK-0859) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) currently undergoing development as… 
Review
2011
Review
2011
Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and… 
Review
2009
Review
2009
Purpose of review Because high-density lipoprotein cholesterol (HDL-C) levels are inversely related to cardiovascular disease… 
Review
2009
Review
2009
Anacetrapib, under development by Merck & Co Inc, is an inhibitor of the cholesterol ester transfer protein (CETP) for the…